Literature DB >> 14499790

Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.

Bret L Hicken1, Diane C Tucker, James C Barton.   

Abstract

OBJECTIVE: The aim of this study was to evaluate patient compliance with phlebotomy therapy of hemochromatosis-associated iron overload.
METHODS: We reviewed medical records of white adults with hemochromatosis and iron overload diagnosed during medical care. We defined three elements of compliance: 1) achieving iron depletion (serum ferritin </= 20 ng/ml); 2) timeliness of phlebotomies on a weekly or biweekly schedule to achieve iron depletion; and 3) participation in therapy to maintain serum ferritin </= 50 ng/ml. We evaluated associations of timeliness of phlebotomy and participation in maintenance therapy with these variables: age at diagnosis, sex, pretreatment serum ferritin concentration, HFE genotype, units of blood removed to achieve iron depletion, and presence or absence of cirrhosis at diagnosis.
RESULTS: A total of 118 patients were evaluable for iron depletion and 142 for maintenance therapy; 96.6% achieved iron depletion, and 33.1% and 43.2% followed weekly and biweekly schedules, respectively. Timeliness was not significantly associated with the variables we evaluated. In the first year of maintenance therapy, 84.0% of patients complied; the percentage of C282Y homozygotes complying was significantly greater than that of other patients. Average compliance with maintenance therapy decreased 6.8% annually; the mean follow-up after achieving iron depletion was 4.1 +/- 2.8 yr (range 0.6-9.7 yr).
CONCLUSIONS: Most patients with hemochromatosis diagnosed in medical care achieve iron depletion with phlebotomy; one-third tolerate and adhere to weekly phlebotomy. There is a constant rate of decline in the percentage of patients who comply with maintenance therapy.

Entities:  

Mesh:

Year:  2003        PMID: 14499790     DOI: 10.1111/j.1572-0241.2003.07292.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.

Authors:  Tatjana Sundic; Tor Hervig; Signe Hannisdal; Jörg Assmus; Rune J Ulvik; Richard W Olaussen; Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-10-23       Impact factor: 3.443

Review 2.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Ruxolitinib for the treatment of patients with polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Elliott F Winton; Moshe Talpaz; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2015-05-17       Impact factor: 2.929

4.  Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study.

Authors:  Ronald T Acton; James C Barton; Leah V Passmore; Paul C Adams; Gordon D McLaren; Catherine Leiendecker-Foster; Mark R Speechley; Emily L Harris; Oswaldo Castro; Jacob A Reiss; Beverly M Snively; Barbara W Harrison; Christine E McLaren
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06-27       Impact factor: 11.382

5.  Potential nonresponse bias in a clinical examination after initial screening using iron phenotyping and HFE genotyping in the hemochromatosis and iron overload screening study.

Authors:  Mark Speechley; James C Barton; Leah Passmore; Helen Harrison; David M Reboussin; Emily L Harris; Charles A Rivers; Margaret Fadojutimi-Akinsiku; Lari Wenzel; Sharmin Diaz
Journal:  Genet Test Mol Biomarkers       Date:  2009-12

6.  Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population.

Authors:  Victor R Gordeuk; David M Reboussin; Christine E McLaren; James C Barton; Ronald T Acton; Gordon D McLaren; Emily L Harris; Jacob A Reiss; Paul C Adams; Mark Speechley; Pradyumna D Phatak; Phyliss Sholinsky; John H Eckfeldt; Wen-Pin Chen; Leah Passmore; Fitzroy W Dawkins
Journal:  Am J Hematol       Date:  2008-08       Impact factor: 10.047

7.  Patient compliance based on genetic medicine: a literature review.

Authors:  Kai Insa Schneider; Jörg Schmidtke
Journal:  J Community Genet       Date:  2013-08-10

8.  Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.

Authors:  Carol Hutchinson; Catherine A Geissler; Jonathan J Powell; Adrian Bomford
Journal:  Gut       Date:  2007-03-07       Impact factor: 23.059

9.  A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

Authors:  Pradyumna Phatak; Pierre Brissot; Mark Wurster; Paul C Adams; Herbert L Bonkovsky; John Gross; Peter Malfertheiner; Gordon D McLaren; Claus Niederau; Alberto Piperno; Lawrie W Powell; Mark W Russo; Ulrich Stoelzel; Wolfgang Stremmel; Louis Griffel; Nicola Lynch; Yiyun Zhang; Antonello Pietrangelo
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

10.  Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases.

Authors:  Maria do Rosário Ferraz Roberti; Handel Meireles Borges Filho; Cláudio Humberto Gonçalves; Flávio Leão Lima
Journal:  Rev Bras Hematol Hemoter       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.